Kylie A. Agnew-Francis

Kylie A. Agnew-Francis

Auto-generated profile, based on publicly available information

Kylie A. Agnew-Francis

School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2016 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
KAKylie A. Agnew‐Francis
Kylie A. Agnew‐Francis
CWCraig Williams
Craig Williams

15 September 2020 in Chemical Reviews
Verified
Journal Article
Closed access
KAKylie A. Agnew-Francis
Kylie A. Agnew-Francis
CWCraig Williams
Craig Williams

24 September 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMario Daniel Garcia Solis
Mario Daniel Garcia Solis
SCSheena M. H. Chua
Sheena M. H. Chua
YLYu-Shang Low
Yu-Shang Low
YLYu-Ting Lee
Yu-Ting Lee
KAKylie Agnew-Francis
Kylie Agnew-Francis
LGLuke W. Guddat
Luke W. Guddat
The increased prevalence of drug-resistant human pathogenic fungal diseases poses a major threat to global human health. Thus, new drugs are urgently required to combat these infections. Here, we demonstrate that acetohydroxyacid synthase (AHAS), the first enzyme in the branched-chain amino acid biosynthesis pathway, is a promising new target for antifungal drug discovery. First, we show that several AHAS inhibitors developed as commercial herbicides are powerful accumulative inhibitors of Candida albicans AHAS (Ki values as low as 800 pM) and have determined high-resolution crystal structures of this enzyme in complex with several of these herbicides. In addition, we have demonstrated that chlorimuron ethyl (CE), a member of the sulfonylurea herbicide family, has potent antifungal activity against five different Candida species and Cryptococcus neoformans (with minimum inhibitory concentration, 50% values as low as 7 nM). Furthermore, in these assays, we have shown CE and itraconazole (a P450 inhibitor) can act synergistically to further improve potency. Finally, we show in Candida albicans-infected mice that CE is highly effective in clearing pathogenic fungal burden in the lungs, liver, and spleen, thus reducing overall mortality rates. Therefore, in view of their low toxicity to human cells, AHAS inhibitors represent a new class of antifungal drug candidates. Significance Human fungal pathogens resistant to conventional therapeutics pose a major threat to global human health. Thus, there is an urgent need to discover new antifungal drugs that act via novel mechanisms of action. Here, we show that commercial herbicides that inhibit acetohydroxyacid synthase (AHAS) have potent and broad-spectrum antifungal activity in vitro and that chlorimuron ethyl, a member of the sulfonylurea herbicide family, has antifungal activity in a mouse model. Thus, this study shows that AHAS inhibitors have strong potential to be developed into potent antifungal therapeutic agents.

28 September 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
KAKylie A. Agnew-Francis
Kylie A. Agnew-Francis
YTYu Cheng Tang
Yu Cheng Tang
XLXin Lin
Xin Lin
YLYu Shang Low
Yu Shang Low
SWShun Jie Wun
Shun Jie Wun
LGLuke W. Guddat
Luke W. Guddat

16 December 2024 in Phytomedicine
Verified
Journal Article
Closed access
NNNirupama A. Nammunige
Nirupama A. Nammunige
KAKylie A. Agnew-Francis
Kylie A. Agnew-Francis
DFDeepani D. Fernando
Deepani D. Fernando
STSara Taylor
Sara Taylor
HLHieng Lu
Hieng Lu
Katja FischerKatja Fischer
Katja Fischer

17 April 2020 in Journal of Natural Products
Verified
Journal Article
Closed access
YTYuen Ping Tan
Yuen Ping Tan
ASAndrei I. Savchenko
Andrei I. Savchenko
KAKylie A. Agnew-Francis
Kylie A. Agnew-Francis
GBGlen M. Boyle
Glen M. Boyle
PBPaul V. Bernhardt
Paul V. Bernhardt
CWCraig Williams
Craig Williams